Pulmonary Hypertension
Congress Materials - Pulmonary Vascular Research Institute (PVRI 2025)
2025 Pulmonary Vascular Research Institute | Jan 29 - Feb 1 | Rio de Janeiro, Brazil
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Macitentan and phosphodiesterase-5 inhibitor as monotherapy or in combination in newly diagnosed patients with pulmonary arterial hypertension: A pooled analysis
Vallerie V McLaughlin, Nicolas Sauvageot, Brian Hennessy, Sumeet Panjabi, Carly J Paoli, Jörg Linder, Bjørn Bayer, Stefan Söderberg, Sean Gaine, Tobias J Lange, Nick H Kim
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.